| Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International, Multicenter, Double Blind, Randomized Placebo Controlled Phase 3 trial (ICR-02/ASCOLT) |
Ongoing |
Aspirin |
3 |
ICR-02/ASCOLT |
King Fahad Medical City (Riyadh) |
| Prospective, multicentre, international Registry of male and female patients newly diagnosed with Atrial Fibrillation and treated with Rivaroxaban |
Ongoing |
Rivaroxaban |
4 |
TRI08890 |
Armed Forces Hospital (Southern Region) |
| Middle East Observational Study in Metastatic Soft Tissue Sarcoma: An epidemiological study on the treatment patterns |
Ongoing |
N/A |
4 |
VEG201319 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| XALIA LEA- Xarelto® for Long-term and Initial Anticoagulation in VenousThromboembolism (VTE) in Latin America,EMEA and Asia |
Ongoing |
Rivaroxaban |
4 |
17237 |
King Fahad Medical City (Riyadh), King Fahad Hospital (Madinah), King Faisal Hospital (Taif), Hira Hospital (Makkah) |
| (FLASH study)A 12-week treatment, multi-center, randomized, doubleblind,double-dummy, parallel group study to assess the efficacy and safety of switching fromsalmeterol/fluticasone to QVA149 (indacaterolmaleate/glycopyrronium bromide) in symptomatic COPD patients |
Ongoing |
Ultibro breezhaler |
4 |
A3405 V01 |
King Fahad Medical City (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz Medical City NG (Jeddah) |
| Early Goal Directed Sedation vs. Standard Care Sedation |
Ongoing |
Dexmedetomidine |
4 |
YS/003 |
King Saud Medical City (Riyadh) |
| Prospective Multicentre Observational Registry Of Treatments And Outcomes In Patients With Chronic |
Ongoing |
N/A |
4 |
ONC-MA1002 |
Aseer Central Hospital |
| Efficacy of Different Mouthwashes in the Reduction of Halitosis: A Randomized, Double Blind, Placebo-Controlled, Crossover Clinical Trial |
Ongoing |
Halita - AO ProRinse |
4 |
PR oo39 |
College of Dentistry King Saud University |
| Observational Prospective STudy In Management of 1st line KRAS Wildtype mCRC with Erbitux™ (Cetuximab)- OPTIM1SE |
Ongoing |
Erbitux (Cetuximab) |
4 |
EMR062202-561 |
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), Prince Sultan Military Medical City (Riyadh), King Fahad Specialist Hospital (Dammam) |
| easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment |
Ongoing |
N/A |
4 |
EMR200104-534 |
King Fahad University Hospital (Al-Khobar), alhabib |
